Jonathan Chang
Stock Analyst at Leerink Partners
(0.58)
# 4,131
Out of 5,163 analysts
76
Total ratings
28.57%
Success rate
-21.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Upgrades: Outperform | $3 → $13 | $7.14 | +82.07% | 11 | Oct 20, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $18.37 | +308.27% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $26.14 | +3.29% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $30.86 | +139.79% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $33.07 | -66.74% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $12.06 | +322.89% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $7.85 | +855.41% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $4.78 | +946.03% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $94.86 | -68.37% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $3.00 | +300.00% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $9.24 | +181.39% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $8.65 | +223.70% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $12.00 | +341.67% | 7 | Aug 5, 2021 |
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $3 → $13
Current: $7.14
Upside: +82.07%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $18.37
Upside: +308.27%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $26.14
Upside: +3.29%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $30.86
Upside: +139.79%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $33.07
Upside: -66.74%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $12.06
Upside: +322.89%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $7.85
Upside: +855.41%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $4.78
Upside: +946.03%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $94.86
Upside: -68.37%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $3.00
Upside: +300.00%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $9.24
Upside: +181.39%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $8.65
Upside: +223.70%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $12.00
Upside: +341.67%